Inclusion Criteria
Concurrent Medication:
Allowed:
- Antiretroviral regimen containing a protease inhibitor and one or two nucleoside reverse transcriptase inhibitors that has not changed in the last 12 weeks.
Patients must have:
- HIV infection with plasma HIV RNA of at least 1,000 copies/ml and less than or equal to 100,000 copies/ml at screening.
Prior Medication:
Allowed:
Naive to or has had less than 8 weeks of at least one nucleoside reverse transcriptase inhibitor and an acceptable regimen of two nucleoside reverse transcriptase inhibitors.
Exclusion Criteria
Concurrent Medication:
Excluded:
- Medications that are contraindicated with ABT-378/ritonavir for the duration of the study, such as midazolam, triazolam, terfenadine, astemizole, cisapride, pimozide, ergotamine and dihydroergotamine.
- Over-the-counter medicine or alcohol, without knowledge or permission of the investigator.
Patients with the following prior conditions are excluded:
- Evidence of acute illness determined by vital signs, physical examination, or laboratory results.
- Clinically significant abnormal ECG results.
- Positive test result for drug abuse with the exception of cannabis, unless the investigator anticipates cannabis use will interfere with compliance with the study.
Prior Medication:
Excluded:
- Investigational drugs with the exception of Amprenavir within 28 days prior to the initiation of study dosing.
- Treatment with a non-nucleoside reverse transcriptase inhibitor.
- Treatment with a protease inhibitor different from the current protease inhibitor for more than 6 weeks prior to current regimen.
- Treatment with more than one protease inhibitor concurrently.
Risk Behavior:
Excluded:
- Active substance abuse, alcohol abuse, psychiatric illness.
- Presumption, by investigator, of poor compliance to regimen.